Companies › 3H Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 3H-10000 | – | Phase 1 | Lung Cancer | Jan 2028 |
| 3HP-2827 FGFR2 inhibitor | FGFR2 | Phase 1 | Solid Tumors With FGFR2 Alterations, Adult | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07354711 | 3H-10000 | Phase 1 | Lung Cancer | Oncology | Jan 2028 |
| NCT06378593 | 3HP-2827 | Phase 1 | Solid Tumors With FGFR2 Alterations, Adult | Oncology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.